Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Tenaya Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Million; Runway to Fund Operations into First Half 2025 SOUTH SAN FRANCISCO, Calif., August 9, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023. “We are looking ahead..."
05/10/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN FRANCISCO, Calif., May 10, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the first quarter ended March 31, 2023. “Tenaya is making ..."
03/08/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Investments of $204 Million; Runway to Fund Operations into First Half 2025 South San Francisco, Calif. – March 8, 2023 – Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2022 and p..."
08/10/2022 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and Capsid Engineering Efforts South San Francisco, Calif. – Aug. 10, 2022—Tenaya Therapeutics, Inc. , a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022. “Tenaya continues to make strides forward in our transition to becoming a fully integrated clinical-stage company and continues to invest ..."
05/11/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates - Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-201 gene therapy -"
09/08/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy